Jadelle Sine Inserter (Levonorgestrel)

Levonorgestrel released from the implant binds to progesterone receptors, suppressing ovulation, thickening cervical mucus to block sperm entry, and altering the uterine lining to make implantation unlikely. These combined actions provide continuous contraceptive protection without daily dosing.

The dosage and number of implants are determined by the prescribing clinician based on the approved product specifications and the patient’s individual health profile. The prescriber decides the appropriate regimen at the time of insertion.

Jadelle Sine Inserter is contraindicated in pregnancy (Category X) and should not be inserted in a pregnant woman. Women who are breastfeeding should discuss potential risks with their healthcare provider, as hormonal exposure may affect milk production and infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with daily oral pills, Jadelle offers a once‑in‑a‑lifetime insertion that provides up to five years of protection, eliminating the need for daily adherence. Unlike intrauterine devices, it does not require uterine placement and can be removed easily if fertility is desired sooner.

The implant should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect it from moisture, direct sunlight, and extreme temperatures to maintain product integrity until the time of insertion.

A qualified healthcare professional inserts the implant subcutaneously in the inner side of the upper arm using a pre‑filled inserter device. The procedure is minimally invasive, takes only a few minutes, and does not require anesthesia in most cases.

Serious risks include ectopic pregnancy, pelvic inflammatory disease, insertion‑site infection, device migration or expulsion, severe allergic reactions, and rare thromboembolic events. Patients should seek immediate medical attention if they experience severe abdominal pain, unusual bleeding, or signs of infection.

Women who are currently pregnant, have a known hypersensitivity to levonorgestrel, have active liver disease, a history of thromboembolic disorders, hormone‑sensitive cancers, or untreated abnormal uterine bleeding should avoid using this implant. A thorough medical evaluation is required before insertion.